Skip to main content
NUWE logo

NUWE · Nuwellis, Inc. · Documents

Track NUWE — free
$3.50 -0.31 (-8.14%) Play latest call Q2 2026 earnings call transcript
Market Cap
$2.06M
Shares
540,912
Volume · Nov 20 4835 Avg daily vol (18 sessions) 2.34M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $8.27M down 5.4% 10-K filed Mar 11, 2026 Quarterly report FY2026 Q3 10-Q filed Nov 12, 2026 Latest results Gross margin expansion and cost cuts narrowed operating loss 8-K filed Nov 12, 2026 Earnings call Q2 2026 earnings call Held Aug 13, 2026
2026
Nov 17
Current report 8-K
Year-to-Date Revenue Up 13%, Gross Margin Rises to 72%

Nuwellis posted an updated investor presentation on November 17, 2026, reporting 13% year-to-date revenue growth, gross margin of 72% versus 59% a year earlier, and cash runway through Q2 2027.

Regulation FD disclosure
4 source passages
On November 17, 2026, Nuwellis, Inc. (the “Company”) posted an updated corporate presentation to its website YTD revenue growth of 13% over the prior-year period YTD gross margins improved to 72% compared to 59% in the prior-year period Cash runway through Q2 2027 supports execution of near-term growth initiatives Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash reaches $8.4 million after $6.7 million financing

Nuwellis raised approximately $6.7 million through a registered direct offering and concurrent Series C warrant exercises. Cash, cash equivalents and restricted cash totaled $8.4 million as of September 30, 2026, supporting operations through the second quarter of 2027.

Read from the MD&A section
4 source passages
Closed a registered direct offering on August 3, 2026, raising approximately $3.4 million in gross proceeds, and received approximately $3.3 million in gross proceeds from the concurrent exercise of Series C Warrants for aggregate proceeds of approximately $6.7 million. As of September 30, 2026, and December 31, 2025, cash, cash equivalents, and restricted cash were $8.4 million and $1.2 million, respectively. We believe our existing capital resources will support operations through the second quarter of 2027, but we will require additional capital to fund operations through the end of fiscal year 2027. Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. Open the document at this passage
Nov 12
Current report 8-K
Gross margin expansion and cost cuts narrowed operating loss

Nuwellis reported third-quarter net sales of $2.2 million, operating loss improved 24% to $2.1 million, gross margin expanded to 69.5%, and cash and cash equivalents reached $8.3 million as of September 30, 2026.

Financial results
5 source passages
MINNEAPOLIS – November 12, 2026 – Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and nine months ended September 30, 2026. Operating loss for the third quarter of 2026 improved 24% year over year to $2.1 million, driven by 430 basis points of gross margin expansion and a 13% reduction in operating expenses, primarily reflecting outsourced manufacturing efficiencies and efforts to align expenses with the highest-priority commercial and strategic programs. Net sales were $2.2 million in the third quarter of 2026, essentially unchanged versus the prior-year quarter, as the prior-year period benefited from fulfilling $0.4 million in accumulated backorders. Third-quarter 2026 gross margin expanded to 69.5% from 65.2% in the prior-year quarter, reflecting higher average selling prices and continued benefits from the Company's contract manufacturing model. Year-to-date gross margin improved to 71.7%, compared with 59.4% in the prior-year period. Strengthened the Company's balance sheet as of September 30, 2026, with $8.3 million in cash and cash equivalents. Open the document at this passage
Oct 23
Current report 8-K Events of Oct 22
Nuwellis Sets One-for-Nine Reverse Stock Split Effective October 26

Nuwellis approved a one-for-nine reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on October 26, 2026. Shares will trade split-adjusted on the Nasdaq Capital Market under NUWE starting October 27, 2026.

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change
2 source passages
the Board approved a one-for-nine reverse stock split of the Company’s issued and outstanding shares of common stock The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on October 26, 2026, and the Company’s common stock will begin trading on a split-adjusted basis when the market opens on October 27, 2026. Open the document at this passage
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.97M ▲ 14.1% Net loss $4.83M Diluted EPS -$26.64
Jun 26
Proxy statement PRE 14A Meeting Jul 24, 2026
Proxy statement AI summary on its way
May 15
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $2.4M ▲ 26.2% Net loss $4.54M Diluted EPS -$2.19
Apr 24
Current report 8-K
Other events AI summary on its way
Apr 2
Proxy statement DEF 14A Meeting Apr 28, 2026
Proxy statement AI summary on its way
Mar 17
Current report 8-K
Other events AI summary on its way
Mar 11
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $8.27M ▼ 5.4% Net loss $17.52M Diluted EPS -$25.39
2025
Nov 12
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $2.22M ▼ 6.3% Net income $468K ▼ 80.2% Diluted EPS $0.56 ▼ 99.2%
Showing 1–50 of 257 documents
Key facts CIK 1506492 CUSIP 67113Y884 13F (30d) 15 filings 12 filers Visit website Investor relations